924 United Therapeutics Corporation $UTHR Shares Bought by Ethic Inc.

Ethic Inc. increased its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 60.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,463 shares of the biotechnology company’s stock after buying an additional 924 shares during the period. Ethic Inc.’s holdings in United Therapeutics were worth $1,335,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in United Therapeutics in the second quarter valued at $2,868,735,000. Janus Henderson Group PLC increased its stake in shares of United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after buying an additional 70,829 shares during the period. Jupiter Topco LLC acquired a new stake in shares of United Therapeutics in the second quarter valued at about $450,140,000. First Trust Advisors LP increased its stake in shares of United Therapeutics by 23.5% in the first quarter. First Trust Advisors LP now owns 270,578 shares of the biotechnology company’s stock valued at $160,447,000 after buying an additional 51,555 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in shares of United Therapeutics during the second quarter worth about $159,522,000. 94.08% of the stock is owned by institutional investors.

Insider Transactions at United Therapeutics

In other news, CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $511.09, for a total transaction of $4,855,355.00. Following the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $165,819,572.87. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 412,238 shares of company stock worth $220,975,006 over the last 90 days. 8.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently commented on UTHR. Leerink Partners lifted their price objective on United Therapeutics from $685.00 to $725.00 and gave the stock an “outperform” rating in a research note on Monday, October 19th. Royal Bank Of Canada increased their target price on shares of United Therapeutics from $697.00 to $725.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. UBS Group set a $725.00 price target on shares of United Therapeutics in a report on Monday, October 19th. Morgan Stanley boosted their price target on shares of United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $850.00 price objective on shares of United Therapeutics in a research note on Monday, October 26th. Twelve investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $676.40.

United Therapeutics Stock Performance

Shares of UTHR opened at $591.17 on Friday. The firm has a market cap of $25.18 billion, a PE ratio of 22.31, a price-to-earnings-growth ratio of 3.94 and a beta of 0.49. United Therapeutics Corporation has a 52-week low of $455.63 and a 52-week high of $614.23. The business’s 50 day moving average price is $542.60 and its two-hundred day moving average price is $536.37.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.01 by ($0.30). The company had revenue of $832.50 million during the quarter, compared to the consensus estimate of $781.14 million. United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The business’s revenue was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $7.16 EPS. Research analysts predict that United Therapeutics Corporation will post 25.08 EPS for the current fiscal year.

United Therapeutics announced that its Board of Directors has approved a share repurchase plan on Thursday, October 22nd that permits the company to repurchase $2 billion in shares. This repurchase authorization permits the biotechnology company to repurchase up to 8.3% of its stock through open market purchases. Share repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

United Therapeutics Company Profile

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.